Navigation Links
PharmaRoth Labs Welcomes Two Respected Physicians to Board of Advisors
Date:6/5/2013

LAS VEGAS, June 5, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to introduce the two newest members of the Company's Board of Advisors, Dr. Jose Alberto Rojas Jimenez and Dr. Alberto Meraz Soria . Dr. Rojas Jimenez recently concluded a clinical trial of Sucanon® on 98 Hispanic pre-diabetic patients, and the findings of the study are to be presented at the European Association for the Study of Diabetes Annual Meeting in Barcelona, Spain on September 23-27, 2013.   

Dr. Rojas Jimenez is a graduate of the prestigious School of Medicine of the Autonomous University of San Luis Potosi. He is Board certified in Internal medicine. His affiliations and membership include: The American British Cowdray Medical Center, American College of Physicians, European Association for the Study of Diabetes, the American Diabetes Association and board member of the Morbi-mortality Health System Federal District. Dr. Rojas Jimenez is a pioneer in the area of ambulatory continuous glucose monitoring as a diagnostic tool in Mexico. He also belongs to the Speakers Bureau of Eli Lilly Mexico, AMK Health Care and P&G. As an expert in Diabetes, he has given over 350 presentations over the past 5 years.

Dr. Meraz Soria also graduated from the School of Medicine of San Luis Potosi, and he is Board Certified in Internal Medicine. Dr. Meraz Soria specialized in Critical Condition patients where he received honorific mention. He is affiliated with the Emergency Service Hospital Sante Fe and a deputy at ABC Pulmonary Physiology and Inhalotherapy Hospital. Dr. Meraz Soria also completed clinical course work thru the Clinical Diabetology Steno Group in Copenhagen, Denmark. Dr. Meraz Soria is coordinating the design and implementation of the new clinical trial that will start in the last quarter of this year.

"I am extremely proud to announce the addition of Drs. Rojas Jimenez and Meraz Soria to our Board of Advisors," stated Luis Lopez , CEO of PharmaRoth. "Both men are highly renowned and have made significant contributions to the medical communities. In addition, Dr. Rojas Jimenez's clinical trial with Sucanon® adds to the growing body of evidence that our product exceeds expectations not just in the stabilization of blood glucose, but also could be used as an alternative for metabolic syndrome that includes reduction in visceral body fat without any side-effects."

About Sucanon®
Sucanon® is approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, containing natural ingredient. It is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers".  Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin.   

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at http://pharmaroth.com/

About PharmaRoth Labs Inc.   
PharmaRoth Labs, Inc. (ROTH) is focused on diabetes prevention and treatments.  The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes.  Sucanon® is a member of a class of diabetic medications called insulin sensitizers.  Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin.  Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.  PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact and Inquiries for Investor Relations:
Michael Irving
Paramount Advisors, LLC
407-878-5462
mike@parvise.com

 


'/>"/>
SOURCE PharmaRoth Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fero Industries, Inc. Changes Name to PharmaRoth Labs, Inc.
2. PharmaRoth Labs, Inc. Files New Dietary Ingredient Notification with the US Food and Drug Administration (FDA)
3. PharmaRoth Labs, Inc. Announces Trading Symbol Change
4. PharmaRoth Labs Signs Definitive Distribution Agreement in Mexico
5. SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
6. SOCMAs Bulk Pharmaceuticals Task Force Welcomes House Passage of FDA Reform Act
7. Global BioClinical Welcomes Jennifer Maas as Senior Consultant
8. Oriel STAT A MATRIX Welcomes New Global Practice Head for Medical Devices and Life Sciences
9. Draeger Welcomes NIOSH Investigation Report
10. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
11. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... that offers insurance and financial preparation services, is providing an update on a ... organization. , Rock City Rescue is a locally recognized nonprofit that provides shelter ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
Breaking Medicine News(10 mins):